Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion

Hematol Oncol. 2021 Apr;39(2):222-230. doi: 10.1002/hon.2831. Epub 2020 Dec 23.

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy. Understanding of the molecular pathogenesis may lead to novel therapeutic targets. Rapamycin, the mammalian target of rapamycin (mTOR) inhibitor, showed inhibitory effects on T-ALL cells. In this study, we showed that rapamycin significantly reduced MYCN mRNA and protein in a concentration-dependent manner in T-ALL cells. Selective knockdown of MYCN by small interfering RNA had similar effects to rapamycin to inhibit T-ALL proliferation and colony formation and to induce G1-phase cell-cycle arrest and apoptosis. The inhibitory effects of rapamycin and MYCN depletion were also found in a Molt-4 xenograft model. Rapamycin and MYCN inhibition suppressed both Wnt/β-catenin and mTOR signaling pathways. The results suggest the effects of rapamycin on adult T-ALL is likely mediated by downregulation of MYCN. The findings suggest MYCN a potential target for the treatment of adult T-ALL. Additionally, dual targeting of mTOR and Wnt/β-catenin pathways may represent a novel strategy in the treatment of adult T-ALL.

Keywords: MYCN; Wnt/β-catenin; adult acute lymphoblastic leukemia; mTOR; rapamycin.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / pharmacology
  • Antibiotics, Antineoplastic / therapeutic use*
  • Cell Proliferation
  • Humans
  • Mice
  • Mice, Inbred NOD
  • N-Myc Proto-Oncogene Protein / metabolism*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Sirolimus / pharmacology
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases / genetics*
  • Wnt Signaling Pathway / genetics*
  • Xenograft Model Antitumor Assays
  • beta Catenin / metabolism*

Substances

  • Antibiotics, Antineoplastic
  • N-Myc Proto-Oncogene Protein
  • beta Catenin
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus